Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820459 | 0.96 | PAOX (0.36) | ACHEPAOXTP53ALOX15LTA4H | |
| SCHEMBL10099931 | 0.92 | PAOX (0.34) | PAOXTP53ALOX15LTA4HNPC1 | |
| SCHEMBL25822772 | 0.88 | ACHE (0.31) | ACHEPAOXTP53ALOX15LTA4H | |
| SCHEMBL19184639 | 0.86 | PAOX (0.36) | ACHEPAOXLTA4HFAAHDNM1 | |
| SCHEMBL24436206 | 0.85 | CYP4F2 (0.36) | LTA4HKDM4E | |
| SCHEMBL5417057 | 0.84 | ACHE (0.42) | ACHETP53ALOX15LTA4HNPC1 | |
| SCHEMBL12792458 | 0.83 | FAAH (0.48) | ACHEPAOXFAAHDNM1 | |
| SCHEMBL889254 | 0.83 | FAAH (0.48) | ACHEPAOXFAAHDNM1 | |
| SCHEMBL12792529 | 0.83 | FAAH (0.48) | ACHEPAOXFAAHDNM1 | |
| SCHEMBL8739614 | 0.83 | PAOX (0.37) | ACHEPAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | ACHE 4870/4885PAOX 1246/4885TP53 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.